Latest argenx News & Updates

See the latest news and media coverage for argenx. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
argenx

Immunology-focused biopharmaceutical company

argenx.com
Headquarters
Boston, United States
Founded year
2008
Company type
Public company
Number of employees
2,100–5,000

Last updated

Latest news about argenx

In short: argenx achieved its first year of operating profitability in 2025, reporting $4.2 billion in revenue and announcing a transition to a new CEO.

Company announcements

  • argenx

    argenx reports strong Q1 progress toward Vision 2030

    Advancements in MG and CIDP drive momentum. Upcoming milestones include data readouts in myositis and MMN.

  • argenx

    argenx reports Q1 2026 financial results

    Global product net sales reach $1.3 billion, up 63% year-over-year. Pipeline updates include upcoming PDUFA for seronegative gMG and topline results for several studies.

  • argenx

    argenx announces AGM results and appoints Karen Massey as CEO

    Tim Van Hauwermeiren becomes Chairperson. All agenda items approved with 90.9% share capital represented.

  • argenx

    argenx presents VYVGART data at AAN 2026

    New studies support broader use in MG subtypes and CIDP, including ocular MG and treatment-naïve patients. Plans sBLA submissions.

Unlock all announcements with a

Media coverage

Unlock all articles with a

Never miss news about argenx

Track argenx and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

argenx competitors & trending companies

Browse news for competitors to argenx and other trending companies.